Research analysts covering PureTech Health.
Recent press releases and 8-K filings for PRTC.
PureTech Health Reports H1 2025 Results and Strategic Focus
PRTC
Earnings
CEO Change
Board Change
- PureTech Health reported a strong cash position of just under $320 million at the end of H1 2025, with consolidated operating expenses reduced to just under $50 million for the first six months of 2025, down from $66.7 million in the same period of 2024.
- The company is prioritizing a "hub and spoke" business model, focusing on three core founded entities: Saleo Therapeutics, Gallup Oncology, and Seaport Therapeutics.
- PureTech maintains a 35.1% equity stake in Seaport Therapeutics, which had a $733 million post-money valuation at its Series B financing and has raised over $325 million since April 2024.
- The company anticipates approximately $300 million in royalty and milestone income over time from Cabenci sales.
- Robert Lyne is serving as interim CEO, and PureTech plans to appoint up to two new non-executive directors to the Board with UK capital markets expertise.
Aug 29, 2025, 10:56 AM
Quarterly earnings call transcripts for PureTech Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more